Drugs / IODINE (131I) METUXIMAB
IODINE (131I) METUXIMAB
also known as
Licartin · (131)i-labeled hab18 f(ab')(2) · 131I-metuximab · Iodine-131-Labeled Metuximab · Metuximab · Metuximab i-131
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00819650 | Dec 2008 → Dec 2009 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT01758679 | Jan 2012 → Nov 2016 | — | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00829465 | Dec 2008 → Dec 2009 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IODINE (131I) METUXIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095356 ↗ |
| Known as | (131)i-labeled hab18 f(ab')(2) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095356 ↗ |
| Known as | 131I-metuximab | “Licartin (generic name,[131I]metuximab injection)” NCT00819650 ↗ |
| Known as | Iodine-131-Labeled Metuximab | “Licartin (Iodine-131-Labeled Metuximab) injection is a antibody drug with new target and the only drug that China own the intellectual property rights.” NCT00829465 ↗ |
| Known as | Licartin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01758679 ↗ |
| Known as | Metuximab | “Licartin (generic name,[131I]metuximab injection)” NCT00819650 ↗ |
| Known as | Metuximab i-131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095356 ↗ |
| Modality | Monoclonal antibody | “radiolabelled monoclonal antibody” PMID 32164877 ↗ Mar 2020 |
| Route | Other | “adjuvant transarterial injection” PMID 32164877 ↗ Mar 2020 |